STOCKHOLM, SE / ACCESSWIRE / February 27, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, February 27, 2024 - Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences:
TD Cowen 44th Annual Health Care Conference
Location: Boston, MA.
Presenter: Ahmed Mousa, CEO
Presentation Date and Time: March 6 at 12:50 PM ET/6:50 PM CET
Webcast Registration: Link
Carnegie Nordic Healthcare Seminar
Location: Stockholm, Sweden
Presenter: Mikael Nygård, VP Operations and Corporate Strategy
Presentation Date and Time: March 6 at 9:00 AM ET/3:00 PM CET
This information was submitted for publication on February 27, 2024, at 08:00 CET.
About Vicore Pharma Holding AB (publ)Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see .
Attachments
Vicore to Present at Upcoming Investor Conferences
SOURCE: Vicore Pharma Holding
View the original press release on accesswire.com
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.